Editors
Johann de Bono
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
Professor Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at the Institute of Cancer Research (ICR), London and The Royal Marsden Hospital (RMH), London, UK. He is also Head of the Clinical Studies Division at the ICR and Director of the Drug Development Unit (DDU) at the Royal Marsden, leading the National Institute for Health Research (NIHR) Experimental Cancer Medicine Centre (ECMC) team and co-leading the NIHR Biomedical Research Centre.
The RMH DDU is one of the world’s largest phase I clinical trials units for cancer, run jointly between the ICR and the RMH. Professor de Bono leads the Prostate Cancer Targeted Therapies team and has also led on multiple phase III trials that have changed the standard-of-care for prostate cancer patients, including trials of the ICR-discovered drugs abiraterone, cabazitaxel and enzalutamide. He has published more than 500 manuscripts, including multiple publications in The New England Journal of Medicine and The Lancet.
Silke Gillessen
Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, University of Bern, Bern, Switzerland;
Division of Cancer Medicine, University of Manchester;
The Christie NHS Foundation Trust, Manchester, UK; Oncology Institute of Southern Switzerland,
Ospedale San Giovanni Bellinzona, Switzerland
Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancer.
Since 2018, Professor Gillessen has been Genitourinary Cancer Systemic Therapy Research Chair at the University of Manchester and Honorary Consultant at The Christie NHS Foundation Trust, Manchester, UK, while continuing to work as a Consultant in the Department of Oncology/Haematology at the Cantonal Hospital St. Gallen, Switzerland.
Professor Gillessen was recently appointed Head of the Department of Medical Oncology, full professor at the Università della Svizzera Italiana (USI) and Director of the Istituto Oncologico della Svizzera Italiana (IOSI) in Lugano and Bellinzona, Switzerland.
Professor Gillessen completed her training in Basel and St. Gallen, Switzerland, and at the Dana-Farber Cancer Institute, Boston, MA, USA. After returning to Switzerland, she built up the medical oncology unit for genitourinary cancer in Cantonal Hospital, St. Gallen and served for two terms as president of the SAKK (Swiss Group for Clinical Cancer Research) GU group. She chaired the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Cancers Group and founded the Advanced Prostate Cancer Consensus Conference (APCCC).
Professor Gillessen has authored more than 150 publications.
Niven Mehra
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
Dr Niven Mehra is a Consultant in Medical Oncology at Radboud University, Nijmegen, Netherlands.
In 2002, he graduated in medicine from the University Medical Center Utrecht, Netherlands. After a PhD in translational research in 2006 (under Emile Voest), he trained in internal medicine from 2006 to 2011 and in medical oncology from 2011 to 2014.
In 2014 he focused on urogenital oncology during a clinical research fellowship at The Royal Marsden NHS Trust and the Institute of Cancer Research (under Johann de Bono), London, UK. His post-doctorate research was centred on biomarker discovery in liquid biopsies using next-generation sequencing techniques, and on the role of immune-suppressive cells driving treatment resistance in prostate cancer.
Since 2016 he has held a staff position as a clinician-scientist focusing on genitourinary cancer and immunotherapy. He is leading a translational research group on biomarker-driven personalised cancer therapy.
Niven Mehra is heading the Prostate Cancer Working Group of the Dutch Uro-Oncology Study (DUOS). He is a member of the European Society for Medical Oncology (ESMO) Educational Publications Working Group and author of peer-reviewed research papers in international journals, cancer textbooks and handbooks.
Yohann Loriot
Gustave Roussy, Department of Cancer Medicine & INSERM U981, Villejuif, France
Dr Yohann Loriot is a physician-scientist in Medical Oncology at the Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.
He trained in Paris, France, graduated in 2009 as a Medical Oncologist, and completed his PhD in 2014. From 2011-2012, he moved as a visiting scientist to the Vancouver Prostate Centre, Vancouver, Canada.
Dr Loriot’s major clinical and translational research focus includes the study of mechanisms mediating progression to lethal disease in urothelial and prostate cancer and the use of this information to develop novel strategies and therapies. He has authored several peer-reviewed research papers in international journals, cancer textbooks and handbooks.
He is a member of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). He is the recipient of a number of grants and awards, including a UNICANCER-Fondation de France grant and an ASCO Young Investigator award 2013.
Contributors
L Albiges
Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine, Villejuif, France
G Baciarello
Gustave Roussy, Université Paris-Saclay, Medical Oncology Department, Villejuif, France
J Bellmunt
Medical Oncology Department, Hospital del Mar, Barcelona, Spain
A Bex
Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust and UCL Division of Surgical and Interventional Science, London, UK
A Birtle
Lancashire Teaching Hospitals, UK; University of Manchester, Manchester, UK
E Castro Marcos
CNIO-IBIMA Genitourinary Cancer Research Unit, Virgen de la Victoria University Hospital, Málaga, Spain
N Clarke
Salford Royal Hospital and The Christie NHS Foundation Trust, Manchester, UK
J de Bono
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
B Escudier
Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine, Villejuif, France
K Fizazi
Gustave Roussy, Université Paris-Saclay, Medical Oncology Department, Villejuif, France
R Flippot
Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine, Villejuif, France
G Gakis
Department of Urology, University Hospital Würzburg, Würzburg, Germany
R Giles
The International Kidney Cancer Coalition, Duivendrecht; Medicom Medical Publishers, Baarn, Netherlands
S Gillessen
Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, University of Bern, Bern, Switzerland;
Division of Cancer Medicine, University of Manchester; The Christie NHS Foundation Trust, Manchester, UK; Oncology
Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
A Haran
Salford Royal Hospital and The Christie NHS Foundation Trust, Manchester, UK
M Ligaj
Department of Pathology, Warsaw Cancer Centre, Warsaw, Poland
N Mehra
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
S Minner
Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
J Oldenburg
Department of Oncology, Akershus University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway
A Omlin
Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, University of Bern, Bern, Switzerland
A Rodriguez-Vida
Medical Oncology Department, Hospital del Mar, Barcelona, Spain
MJ Roobol
Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
G Sauter
Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
M Schmidinger
Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer
Center, Vienna, Austria
E Senkus
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
A Sherif
Umeå University, Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden
R Shotton
Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
A Stenzl
Department of Urology, Eberhard-Karls-University, Tübingen, Germany
T Tandstad
The Cancer Clinic, St. Olav’s University Hospital and the Norwegian University of Science and Technology, Trondheim, Norway
C Thellenberg Karlsson
Umeå University, Department of Radiation Sciences, Oncology, Umeå, Sweden
T Todenhöfer
Department of Urology, Eberhard-Karls-University, Tübingen, Germany
P Umari
Division of Urology, Maggiore della Carità Hospital, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
A Volpe
Division of Urology, Maggiore della Carità Hospital, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Declarations of Interest
L Albiges: Institution: Ipsen, Merck Sharp & Dohme, EUSA Pharma, AVEO Oncology, Pfizer, Novartis,Bristol-Myers Squibb, Corvus Pharmaceuticals.
G Baciarello: No conflict of interest.
J Bellmunt: Advisory role: Genentech, Merck Sharp & Dohme, Pfizer, Glaxo SmithKline, Bristol-Myers Squibb, AstraZeneca, Pierre-Fabre, Sanofi-Aventis, Astellas, OncoGenex, Janssen; lectures: Pfizer, Merck Sharp & Dohme, Glaxo SmithKline, Novartis, Pierre-Fabre, Astellas, Bristol-Myers Squibb; research funding: Takeda, Pfizer, Novartis, Sanofi-Aventis.
A Bex: Advisory boards: Pfizer, Bristol-Myers Squibb, Novartis, EISAI, Roche, Ipsen; educational grant: Pfizer.
A Birtle: Advisory boards: Janssen, Sanofi Genzyme, Bayer, Novartis Astellas, Roche.
E Castro Marcos: No conflict of interest.
N Clarke: No conflict of interest.
J de Bono: His institution has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income). Advisory boards: AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Roche/Genentech, Genmab, Glaxo SmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Sanofi-Aventis, Taiho; his institution has received funding or other support for his research work from AstraZeneca, Astellas, Bayer, Genentech, Glaxo SmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Sanofi-Aventis, Taiho; he has been the Chief Investigator/Principal Investigator of many industry-sponsored clinical trials.
B Escudier: Honoraria: Bristol-Myers Squibb, EUSA Pharma, Ipsen, Novartis, Pfizer, Roche/Genentech; consulting or advisory role: AVEO, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Novartis, Pfizer, Roche/Genentech; travel, accommodation, expenses: Bristol-Myers Squibb, Ipsen, Pfizer, Roche/Genentech.
K Fizazi: No conflict of interest.
R Flippot: No conflict of interest.
G Gakis: No conflict of interest.
R Giles: Advisory boards: Pfizer, Merck KGaA, Ipsen.
S Gillessen: Advisory role and independent data monitoring committee (IDMC) (compensated, personally): MaxiVax, Janssen, Sanofi, Orion, Roche; advisory role and IDMC (compensated, institutional): AAA International, Astellas, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin, Janssen, Menarini, Orion, Roche, Sanofi; advisory role (uncompensated): Nectar, ProteoMediX; speaker’s bureau (compensated, personally): Janssen; speaker’s bureau (compensated, institutional): Janssen, Novartis; co-inventor on patent application (WO 2009138392 A1) for a method for biomarker discovery (granted in China, Europe, Japan and the USA).
A Haran: No conflict of interest.
M Ligaj: No conflict of interest.
N Mehra: Advisory role (compensated, institutional): Roche, Merck Sharp & Dohme, Bayer, Astellas, Janssen; research support (institutional): Astellas, Janssen, Pfizer, Roche, Sanofi Genzyme; travel support: Astellas, Merck Sharp & Dohme.
S Minner: No conflict of interest.
J Oldenburg: No conflict of interest.
A Omlin: Advisory role (compensated, institutional): AstraZeneca, Astellas, Bayer, Janssen, Molecular Partners, Merck Sharp & Dohme, Pfizer, Roche, Sanofi-Aventis; research support (institutional): TEVA, Janssen; travel support: Astellas, Bayer, Janssen, Sanofi-Aventis; speaker’s bureau (compensated, institutional): Bayer, Astellas.
A Rodriguez-Vida: Advisory role: Merck Sharp & Dohme, Pfizer, Bristol-Myers Squibb, Astellas, Janssen, Bayer, Roche; lectures: Pfizer, Merck Sharp & Dohme, Astellas, Bristol-Myers Squibb, Janssen, AstraZeneca, Roche, Bayer, Sanofi-Aventis; research funding: Takeda, Pfizer, Merck Sharp & Dohme.
MJ Roobol: No conflict of interest.
G Sauter: No conflict of interest.
M Schmidinger: Honoraria for lectures or advisory boards from Pfizer, Bristol-Myers Squibb, Novartis, Roche, Ipsen, Exelixis, Merck Sharp & Dohme, Astellas, EUSA, EISAI.
E Senkus: No conflict of interest.
A Sherif: No conflict of interest.
R Shotton: No conflict of interest.
A Stenzl: Advisory role/consultancy (personal): Ipsen, Roche, Janssen, Alere; advisory role: Bristol-Myers Squibb, Stebabiotech, Synergo, Ferring; speaker’s bureau: Janssen, Ipsen, Sanofi-Aventis,
CureVac, Astellas, Amgen; research support (institution): Johnson & Johnson, Roche, Cepheid, Amgen, Bayer, CureVac, Immatics Biotechnologies GmbH, GenomeDx Biosciences, Novartis, KarlStorz.
T Tandstad: No conflict of interest.
C Thellenberg Karlsson: No conflict of interest.
T Todenhöfer: Consultancy for Ipsen, Merck Sharp & Dohme, Roche, Bristol-Myers Squibb.
P Umari: No conflict of interest.
A Volpe: No conflict of interest.
